Skip to main content

Harmony Biosciences Holdings, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Three Months Ended September 30, · ​ · Nine Months Ended September 30,
​ · 2025 · 2024 · 2025 · 2024
Net product revenue​$239,455​$186,038​$624,677​$513,467
Cost of product sold​59,650​42,778​129,797​102,406
Gross profit​179,805​143,260​494,880​411,061
Operating expenses:​​​​
Research and development​54,962​25,387​139,661​111,159
Sales and marketing​29,549​27,576​90,333​83,316
General and administrative​29,807​28,587​94,974​81,487
Total operating expenses​114,318​81,550​324,968​275,962
Operating income​65,487​61,710​169,912​135,099
Other expense, net​(106)​(124)​(575)​(228)
Interest expense​​(3,621)​​(4,348)​​(11,103)​(13,287)
Interest income​5,730​4,932​16,070​14,065
Income before income taxes​67,490​62,170​174,304​135,649
Income tax expense​(16,625)​(16,077)​(38,103)​(39,631)
Net income​$50,865​$46,093​$136,201​$96,018
Unrealized income on investments​118​733​291​497
Comprehensive income​$50,983​$46,826​$136,492​$96,515
EARNINGS PER SHARE:​​​​
Basic​$0.88​$0.81​$2.36​$1.69
Diluted​$0.87​$0.79​$2.32​$1.66
Weighted average number of shares of common stock - basic​57,550,902​56,870,234​57,655,272​56,815,167
Weighted average number of shares of common stock - diluted​58,717,910​58,103,963​58,738,361​57,754,016

UNAUDITED CONDENSED CONSOLIDATED

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.